» Articles » PMID: 39030451

Down-regulation of NF-κB Signalling by Methanolic Extract of Viola Odorata (L.) Attenuated in Vivo Inflammatory and Angiogenic Responses

Overview
Specialty Pharmacology
Date 2024 Jul 19
PMID 39030451
Authors
Affiliations
Soon will be listed here.
Abstract

Intractable inflammation plays a key role in the progression of autoimmune diseases such as rheumatoid arthritis. Oedema and angiogenesis are the hall marks of chronic inflammation. The current study was aimed to investigate the pharmacological effects of the methanolic extract of Viola odorata (Vo.Me) on inflammation induced oedema and angiogenesis, and to identify the active principles and explore the molecular mechanisms thereof. Various models of inflammation were utilized in rats, including carrageenan- and histamine-induced acute oedema, as well as chronic models of Complete Freund's Adjuvant (CFA)-induced arthritis and cotton pellet-induced granuloma. Anti-angiogenic activity was evaluated by CAM assay followed by quantification of phytoconstituents through HPLC. Effect of Vo.Me  treatment on the expression of various mediators (PGE-2 and NO) and genes (IL-1β, TNF-α, NF-κB, and COX-2) were explored by qPCR and ELISA assays. HPLC analysis showed the presence of quercetin, chlorogenic acid, gallic acid, benzoic acid, m-coumaric acid, p-coumaric acid, synergic acid, caffeic acid, vanillic acid, sinapic acid, and cinnamic acid in Vo.Me. Significant dose-dependent inhibition of rats' paw oedema was observed in the Vo.Me administered groups (p < 0.05) in both acute and chronic inflammatory models. Moreover, at a dosage of 500 mg/kg, Vo.Me exhibited a comparable anti-inflammatory effect to indomethacin (p > 0.05). Additionally, Vo.Me demonstrated a remarkable anti-granulomatous activity. Histopathological findings demonstrated amelioration of inflammation in animal paws which were treated with Vo.Me and indomethacin. CAM assay also displayed significant inhibitory effect of Vo.Me on the blood vasculature growth. Vo.Me treatment also caused relatively less gastric irritation and hepatic damage as compared to indomethacin. At a molecular level, the down-regulation of NF-κB signalling  leading to the decreased activation of pro-inflammatory mediators (such as IL-1β, TNF-α, and COX-2) and their downstream molecules including prostaglandin E-2 (PGE-2) and nitric oxide (NO), is suggested to be responsible for these diverse anti-inflammatory effects. These findings confirmed the promising anti-inflammatory and anti-angiogenic activities of Vo.Me, which warrant bench-to-bedside translational studies to assess its safety and suitability for clinical usage.

Citing Articles

Model-based fed-batch cultivation of plant cells exhibiting antimalarial and anticancer activity.

Babu R, Veeramani M, Aadinath W, Muthuvijayan V, Singh S, Srivastava S Front Bioeng Biotechnol. 2025; 13:1528570.

PMID: 39944222 PMC: 11815595. DOI: 10.3389/fbioe.2025.1528570.

References
1.
Adesso S, Russo R, Quaroni A, Autore G, Marzocco S . Extract Attenuates Inflammation and Oxidative Stress in Intestinal Epithelial Cells via NF-κB Activation and Nrf2 Response. Int J Mol Sci. 2018; 19(3). PMC: 5877661. DOI: 10.3390/ijms19030800. View

2.
Alamil J, Paudel K, Chan Y, Xenaki D, Panneerselvam J, Singh S . Rediscovering the Therapeutic Potential of Agarwood in the Management of Chronic Inflammatory Diseases. Molecules. 2022; 27(9). PMC: 9104417. DOI: 10.3390/molecules27093038. View

3.
Andleeb F, Asif M, Yaseen H . Exploration of molecular mechanisms responsible for anti-inflammatory and anti-angiogenic attributes of methanolic extract of Viola betonicifolia. Inflammopharmacology. 2022; 30(4):1459-1474. DOI: 10.1007/s10787-022-00990-4. View

4.
Bindu S, Mazumder S, Bandyopadhyay U . Non-steroidal anti-inflammatory drugs (NSAIDs) and organ damage: A current perspective. Biochem Pharmacol. 2020; 180:114147. PMC: 7347500. DOI: 10.1016/j.bcp.2020.114147. View

5.
Chen L, Deng H, Cui H, Fang J, Zuo Z, Deng J . Inflammatory responses and inflammation-associated diseases in organs. Oncotarget. 2018; 9(6):7204-7218. PMC: 5805548. DOI: 10.18632/oncotarget.23208. View